Wearable Insoles for Diabetic Foot Ulcers

(WIREDUP Trial)

Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests special insoles designed to help prevent foot ulcers in people with diabetes. The goal is to determine if these insoles, used alongside standard care, can reduce foot sores and improve quality of life. Participants must have diabetes with a previously healed foot ulcer and be able to walk at least 30 steps, with or without a cane or walker. The study aims to assess the effectiveness and ease of use of the insoles for those at high risk of foot problems. As an unphased trial, it offers participants the chance to contribute to important research that could enhance diabetic foot care for many.

What prior data suggests that the Orpyx Sensory Insole System is safe for use in reducing plantar ulceration?

Research has shown that the Orpyx Sensory Insole System is generally easy for patients to use. Studies have found that these insoles effectively lower the chances of diabetic foot ulcers recurring, without causing major side effects. In one study, patients using the Orpyx insoles experienced a 71% reduction in foot ulcers. This suggests that the insoles are both effective and safe for preventing foot problems in people with diabetes. Overall, reports of serious negative effects have not emerged, making the insoles a promising choice for those at high risk of developing foot ulcers.12345

Why are researchers excited about this trial?

Researchers are excited about the Orpyx Sensory Insole System because it offers a unique approach to managing diabetic foot ulcers. Unlike traditional treatments like wound dressings and offloading shoes, this system uses advanced sensor technology embedded in wearable insoles. These sensors provide real-time feedback to patients, helping them adjust their foot pressure and reduce the risk of ulcers developing or worsening. This proactive method empowers patients to take control of their foot health, potentially reducing the need for more invasive treatments down the line.

What evidence suggests that the Orpyx Sensory Insole System is effective for reducing diabetic foot ulcers?

Research has shown that the Orpyx Sensory Insole System, which participants in this trial will use, can significantly reduce diabetic foot ulcers. In one study, individuals who wore these insoles for more than 4.5 hours daily experienced an 86% decrease in recurring foot ulcers. Another study demonstrated a 71% reduction in new ulcers for those using the insoles. These insoles track foot pressure and provide feedback, helping individuals with diabetic nerve damage better sense their feet, thus preventing ulcers. Overall, evidence suggests these insoles effectively prevent foot ulcers in high-risk individuals.13567

Who Is on the Research Team?

CH

Caitlyn Hicks, MD

Principal Investigator

Johns Hopkins University

Are You a Good Fit for This Trial?

This trial is for people with diabetes who have nerve damage in their feet (peripheral neuropathy) and are at high risk of getting foot ulcers again. Participants should not currently have an active foot ulcer.

Inclusion Criteria

Amputations compatible with use of insoles at physician discretion (e.g. Transmetatarsal Amputation)
I have been diagnosed with type 1 or type 2 diabetes.
I am over 18 years old.
See 7 more

Exclusion Criteria

Dementia
Physician discretion
I have an infection or gangrene in my lower leg or foot.
See 13 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants use the Orpyx SI Sensory Insole system as an adjunct to standard care to reduce plantar ulceration

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Orpyx Sensory Insole System

Trial Overview

The study compares the use of a special wearable insole system called Orpyx SI, along with usual care, to just usual care alone. The goal is to see if the insoles help prevent new foot ulcers in high-risk diabetic patients.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Orpyx Sensory Insole System InterventionExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Johns Hopkins University

Lead Sponsor

Trials
2,366
Recruited
15,160,000+

Orpyx Medical Technologies Inc.

Industry Sponsor

Trials
3
Recruited
580+

Citations

Orpyx Launches Sensory Insole Program to Combat >$80B ...

individuals who wore an earlier-generation Orpyx insoles for 4.5+ hours daily experienced an 86% reduction in foot re-ulceration

A Multi-Faceted Digital Health Solution for Monitoring and ...

Innovative intelligent insole system reduces diabetic foot ulcer recurrence at plantar sites: A prospective, randomised, proof-of-concept study.

Evaluating the Effectiveness of Plantar Sensory Insoles ...

Patient case series showed of the 40 participants provided with the sensory insole system, average daily use was 8.9 hours per day, and remained steady over ...

News

Orpyx's sensory insoles and digital health platform will be used in a $5M NIH-funded trial led by Johns Hopkins to prevent diabetic foot ulcers.

Innovative intelligent insole system reduces diabetic foot ...

Our study shows foot pressure might be able to be used as a feedback signal to compensate for the loss of sensation because of diabetic peripheral neuropathy ...

6.

orpyx.com

orpyx.com/

Orpyx | We're in this together. Every step of the way.

Innovative intelligent insole system reduces diabetic foot ulcer recurrence at plantar sites: A prospective, randomized, proof-of-concept study.

Orpyx Insoles for Diabetic Foot (WIREDUP Trial)

This trial tests special insoles called Orpyx Sensory Insoles to determine if they can help prevent foot ulcers in people with diabetes.